Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008 by Worni, Mathias et al.
CLINICAL RESEARCH
Cholecystectomy Concomitant with Laparoscopic Gastric
Bypass: ATrend Analysis of the Nationwide Inpatient Sample
from 2001 to 2008
Mathias Worni & Ulrich Guller & Anand Shah &
Mihir Gandhi & Jatin Shah & Dimple Rajgor &
Ricardo Pietrobon & Danny O. Jacobs & Truls Østbye
Published online: 20 December 2011
# Springer Science+Business Media, LLC 2011
Abstract
Background Gallstone formation is common in obese
patients, particularly during rapid weight loss. Whether a
concomitant cholecystectomy should be performed during
laparoscopic gastric bypass surgery is still contentious. We
aimed to analyze trends in concomitant cholecystectomy and
laparoscopic gastric bypass surgery (2001–2008), to identify
factors associated with concomitant cholecystectomy, and to
compare short-term outcomes after laparoscopic gastric by-
pass with and without concomitant cholecystectomy.
Methods We used data from adults undergoing laparoscopic
gastric bypass for obesity from the Nationwide Inpatient
Sample. The Cochran–Armitage trend test was used to as-
sess changes over time. Unadjusted and risk-adjusted gen-
eralized linear models were performed to assess predictors
of concomitant cholecystectomy and to assess postoperative
short-term outcomes.
Results A total of 70,287 patients were included: mean age
was 43.1 years and 81.6% were female. Concomitant cho-
lecystectomy was performed in 6,402 (9.1%) patients. The
proportion of patients undergoing concomitant cholecystec-
tomy decreased significantly from 26.3% in 2001 to 3.7% in
2008 (p for trend<0.001). Patients who underwent concom-
itant cholecystectomy had higher rates of mortality (unad-
justed odds ratios [OR], 2.16; p00.012), overall
postoperative complications (risk-adjusted OR, 1.59; p0
0.001), and reinterventions (risk-adjusted OR, 3.83; p<
0.001), less frequent routine discharge (risk-adjusted OR,
0.70; p00.05), and longer adjusted hospital stay (median
difference, 0.4 days; p<0.001).
Conclusions Concomitant cholecystectomy and laparo-
scopic gastric bypass surgery have decreased significantly
over the last decade. Given the higher rates of postoperative
complications, reinterventions, mortality, as well as longer
hospital stay, concomitant cholecystectomy should only be
considered in patients with symptomatic gallbladder disease.
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Introduction
Obesity has reached epidemic proportions in the USA and,
with the prevalence of obesity of approximately 34% [1],
bariatric surgery is performed more frequently than ever
before [2, 3]. Weight loss surgery is a fast and mostly
permanent way to lose weight for those with severe obesity
[4, 5]. Bariatric surgery not only decreases morbidity and
mortality in obese patients [4, 6], but also has been estimat-
ed to reduce health care costs up to 45% by 5 years postop-
eratively [6, 7]. However, the formation of gallstones in
these patients remains a subject of concern [8, 9]. Despite
the benefits of bariatric surgery, obesity and rapid weight
loss increase the risk of gallstone formation [8–10] with a
1-year cumulative incidence after bariatric surgery ranging
from 30% to 53% [11, 12]. Although routine prophylactic
cholecystectomy [13–15] can be performed to remove gall-
stones or to prevent gallstone formation, several alternative
approaches have been suggested regarding the management
of the gallbladder during bariatric surgery. These include
cholecystectomy only after preoperatively detected gallblad-
der pathology by ultrasound [16, 17], cholecystectomy after
intraoperative verification of gallstones with ultrasound [11,
18], routine administration of ursodeoxycholic acid to all
patients to prevent gallstone formation [11, 19, 20], and no
treatment for asymptomatic patients before or after surgery
[21, 22]. Yet, little is known about the nationwide rate of
cholecystectomies in laparoscopic gastric bypass surgery and
about the short-term outcomes compared to laparoscopic gas-
tric bypass surgery without concomitant cholecystectomy.
We undertook a secondary data analysis using the Na-
tionwide Inpatient Sample (NIS) database to assess trends in
concomitant cholecystectomy among patients undergoing
laparoscopic gastric bypass procedures. We also sought to
identify potential predictors of concomitant cholecystectomy
among patients undergoing laparoscopic gastric bypass sur-
gery and to determine whether there were differences between
short-term postoperative outcomes between patients with and
without concomitant cholecystectomy.
Methods
The Institutional Review Board approved the study proto-
col. We conducted a secondary analysis of data from 2001 to
2008 from a national administrative database, the NIS, a
Healthcare Cost and Utilization Project. In the USA, the NIS
represents the largest all-payer inpatient database: five to
eight million inpatients are included annually. NIS data are
based on both clinical discharge diagnosis and resource use
for about 20% of all hospital discharges per year of nonfed-
eral, short-term, general, and other specialty hospitals in the
USA. The data set is stratified by various hospital
characteristics, such as region, urban/rural locations, teach-
ing status, number of beds, and ownership. All hospital
discharges are included in this publicly available, accredited
database. No personal identifiers are contained in the NIS.
We identified our sample from the NIS database
based on the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM). All
patients 18 years of age or older undergoing laparoscop-
ic gastric bypass surgery for obesity were included. We
defined obesity using the following ICD-9 diagnosis
codes: V85.3x (body mass index [BMI] 35.0–39.9 kg/m2),
V85.4 (BMI >40 kg/m2), V77.8 (obesity), 278.0 (over-
weight and obesity), 278.00 (obesity unspecified),
278.01 (morbid obesity), and 278.02 (overweight). Lap-
aroscopic gastric bypass procedure was either defined as
ICD-9 44.38 (laparoscopic gastric bypass) or a combination of
a procedure code for open gastric bypass (44.31, 44.39,
and 44.3) and either a procedure code for laparoscopy
(54.21), laparoscopic cholecystectomy (51.23), laparo-
scopic lysis of adhesions (54.51), or an ICD-9 diagnosis
code for conversion from laparoscopic to open surgery
(V64.4, V64.41). Patients with the following ICD-9 diagnosis
codes were excluded from our analysis: 253.8 (adiposogenital
dystrophy), 259.9 (obesity of endocrine origin NOS), 150–
159.9 (gastrointestinal track neoplasm), 555.0–556.9 (inflam-
matory bowel disease), and 557.0–558.9 (noninfectious colitis).
Patients admitted through the emergency department were
excluded.
The primary outcome of interest was change from 2001
to 2008 in the proportion of patients who underwent chole-
cystectomy during a laparoscopic gastric bypass procedure.
Patients undergoing concomitant cholecystectomy were
identified through ICD-9 procedure codes for cholecystecto-
my (51.2, 51.21–51.24). Demographic characteristics includ-
ed age, gender, ethnicity (White, Black, Hispanic, other), ZIP
code-related household income per year (1, $1–34,999; 2,
$35,000–44,999; 3, ≥$45,000), and insurance status (Medi-
care, Medicaid, private including health maintenance
organization (HMO), others). Hospital characteristics in-
cluded hospital region (South, Northeast, Midwest,
West), hospital location/teaching status (rural, urban
nonteaching, urban teaching), and hospital volume (in
quintiles).
We used a modified comorbidity index based on the
Charlson index [23], developed for use with administrative
data and previously described by Deyo et al. [24]. Patients
were divided into three groups: Deyo category 0, 1, or >1.
Gallbladder disease was identified through the following
ICD-9 diagnosis codes: 574.0–574.91 and 575.0–575.9.
We further identified intraoperative and postoperative
complications as well as reinterventions through ICD-9
codes as listed in the Appendix modified from Guller et al.
[25]. We only included complications that were clearly
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identifiable as postoperative to avoid overlap with preoper-
ative comorbidity. In addition, we captured data on in-
hospital mortality, discharge status (routine, nonroutine),
and length of hospital stay.
Statistical Analysis
Demographic characteristics were assessed for the entire
study period using means and standard deviations or counts
and percentages. Comparisons were performed using Stu-
dent’s t test and chi-squared test where appropriate.
We determined the annual incidence of concomitant cho-
lecystectomy by dividing the number of patients undergoing
laparoscopic gastric bypass procedures combined with con-
comitant cholecystectomy by the number of patients under-
going laparoscopic gastric bypass surgery performed for each
year. The trend for concomitant cholecystectomy was ascer-
tained using the Cochran–Armitage trend test for all patients
undergoing laparoscopic gastric bypass surgery as well as for
subgroups of patients with and without gallbladder disease.
To identify predictors of concomitant cholecystectomy, such
as year of procedure (to assess changes over time), age, gender,
ethnicity, ZIP code-related income, insurance status, hospital
region, hospital location/teaching status, hospital volume, Deyo
score, and gallbladder disease among patients undergoing lap-
aroscopic gastric bypass surgery, we performed univariate and
multivariate logistic regression analysis. Odds ratios (OR) and
95% confidence intervals (95% CI) were calculated.
Using the same predictors as above, we compared intra-
operative and postoperative adverse events as well as hos-
pital discharge using univariate and multivariate logistic
regression. The same set of covariates was used in multiple
linear regression analysis for length of hospital stay. Year of
operation was added as a covariate to account for outcome
improvements in laparoscopic gastric bypass surgery over
time. Since length of hospital stay was substantially skewed
to the right, we performed log transformation before
performing multiple linear regression analysis. The esti-
mates were retransformed using exponential formula, and
median values as well as the 95% CI are provided. Due to
the very small number of events for retained foreign bodies,
bile duct lesions, and mortality, we did not perform multi-
variate analysis for those outcomes.
Ethnicity was missing for 20.3% of the subjects. Multi-
variate regression analyses were, therefore, performed with
and without ethnicity in the model. Since the results from
the two models were very similar, only the model including
ethnicity is presented.
A significance level (α) of 0.05 was used for all analyses.
p values for all tests were two-sided. All statistical calcu-
lations were performed using Stata/SE version 10 (Stata
Corporation, College Station, TX, USA).
Results
We evaluated data from a total of 70,287 patients undergoing
laparoscopic gastric bypass surgery for obesity between 2001
and 2008. There were 57,332 (81.6%) women and mean age
was 43.1 (SD, 10.8) years. Overall, 6,402 (9.1%) patients
underwent concomitant cholecystectomy and 6,245 (8.9%)
patients suffered from any gallbladder disease. Patients who
underwent cholecystectomy had fewer comorbidities as mea-
sured by the Deyo score before the operation than those who
did not. Subject characteristics are provided in Table 1.
The proportion of patients undergoing concomitant chole-
cystectomy during the laparoscopic gastric bypass procedure
decreased from 26.3% to 3.7% over the 8-year time period (p
for trend<0.001) (Table 1, Fig. 1). This trend holds true for
both patients with and without gallbladder disease, whereas
the trend is more pronounced among patients without gall-
bladder disease (p for trend<0.001 for both) (Fig. 2a, b).
Using 2001 as reference, year of operation was a strong
negative predictor for concomitant cholecystectomy with
risk-adjusted OR decreasing from 0.20 (95% CI, 0.13–
0.32; p<0.001) (relative to 2001) for 2002 to 0.042 (95%
CI, 0.028–0.063; p<0.001) in 2008 (Table 2). Patients op-
erated in hospitals either located in rural (risk-adjusted OR,
0.51; 95% CI, 0.31–0.86; p00.011) or teaching hospitals in
urban areas were less likely to undergo cholecystectomy
(risk-adjusted OR, 0.54; 95% CI, 0.46–0.62; p<0.001) com-
pared to urban nonteaching hospitals. The strongest predic-
tor of concomitant cholecystectomy was the presence of any
gallbladder disease (risk-adjusted OR, 1,400.1; 95% CI,
1,187.7–1,650.4; p<0.001).
Intraoperative complications occurred in 2.37% (n0
1,516) of patients without concomitant cholecystectomy
and in 2.86% (n0183) of patients with concomitant chole-
cystectomy (p00.016) (Table 3). After adjusting for multi-
ple confounders, no difference for overall intraoperative
complications between the two groups was observed (risk-
adjusted OR, 1.22; 95% CI, 0.80–1.85; p00.36). In spite of
the fact that the patients who underwent cholecystectomy
had fewer comorbidities than those who did not, patients
undergoing concomitant cholecystectomy showed a higher
rate of postoperative complications (6.22%, n0398) than
patients without concomitant cholecystectomy (5.06%, n0
3,235) (p<0.001). Even after adjustment for potential con-
founders, this difference remained significant (OR, 1.59;
95% CI, 1.21–2.10; p00.001). The following postoperative
adverse events showed higher risk-adjusted relative OR in
patients undergoing concomitant cholecystectomy: postop-
erative infections (OR, 3.31; 95% CI, 1.58–6.94; p00.002),
pulmonary complications (OR, 2.29; 95% CI, 1.53–3.42;
p<0.001), and gastrointestinal complications (OR, 1.88;
95% CI, 1.21–2.91; p00.005). The in-hospital rate of post-
operative reinterventions was higher in patients with
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Table 1 Characteristics of patients undergoing laparoscopic gastric bypass surgery for obesity
Variable Without concomitant
cholecystectomy
(n063,885, 90.89%)
With concomitant
cholecystectomy
(n06,402, 9.11%)
p value
Age (mean, SD) 43.10 (10.9) 42.76 (10.5) 0.019
Gender
Female 51,874 (81.2) 5,458 (85.3) <0.001
Male 11,713 (18.3) 923 (14.4)
Missing 298 (0.5) 21 (0.3)
Ethnicity
White 38,335 (60.0) 4,021 (62.8) <0.001
Black 5,710 (8.9) 474 (7.4)
Hispanic 4,488 (7.0) 557 (8.7)
Other 2,276 (3.6) 161 (2.5)
Missing 13,076 (20.5) 1,189 (18.6)
ZIP code-related income
1–34,999 12,279 (19.2) 1,229 (19.2) 0.61
35,000–44,999 16,154 (25.3) 1,586 (24.8)
44,999 or more 33,595 (52.6) 3,404 (53.2)
Missing 1,857 (2.9) 183 (2.9)
Insurance
Private including HMO 49,733 (77.8) 5,335 (83.3) <0.001
Medicare 4,502 (7.0) 354 (5.5)
Medicaid 3,312 (5.2) 227 (3.6)
Other 6,049 (9.5) 475 (7.4)
Missing 289 (0.5) 11 (0.2)
Hospital region
South 20,191 (31.6) 1,995 (31.2) <0.001
Northeast 14,394 (22.5) 1,190 (18.6)
Midwest 10,083 (15.8) 1,099 (17.2)
West 19,217 (30.1) 2,118 (33.1)
Hospital location/teaching
Rural 1,446 (2.3) 160 (2.5) <0.001
Urban nonteaching 29,373 (46.0) 3,545 (55.4)
Urban teaching 33,066 (51.8) 2,697 (42.1)
Hospital volume (quintiles)
<Q1 (1–58) 12,502 (19.6) 1,728 (27.0) <0.001
Q1–Q2 (59–114) 12,776 (20.0) 1,328 (20.7)
Q2–Q3 (115–173) 13,324 (20.9) 870 (13.6)
Q3–Q4 (174–289) 12.924 (20.2) 1,065 (16.6)
>Q4 (>289) 12,359 (19.4) 1,411 (22.0)
Deyo score
0 48,881 (76.5) 5,090 (79.5) <0.001
01 10,914 (17.1) 910 (14.2)
>1 4,090 (6.4) 402 (6.3)
Gallbladder disease
Yes 523 (0.82) 5,722 (89.38) <0.001
No 63,362 (99.18) 680 (10.62)
Year
2001 498 (73.7) 178 (26.3) <0.001a
2002 2,178 (81.4) 497 (18.6)
OBES SURG (2012) 22:220–229 223
concomitant cholecystectomy (0.73%, n047) than in
patients without concomitant cholecystectomy (0.47%, n0
302) (p00.005). This difference remained in multivariate re-
gression analysis (risk-adjusted OR, 3.83; 95% CI, 2.00–7.34;
p<0.001). The unadjusted risk of in-hospital mortality was
2.16 times higher for patients undergoing concomitant chole-
cystectomy than for the others (95% CI, 1.19–3.94; p00.012).
Routine discharge for patients with concomitant cholecys-
tectomy was lower than for patients without concomitant
cholecystectomy (risk-adjusted OR, 0.70; 95% CI, 0.49–
1.00; p00.05) (Table 3). Patients undergoing cholecystectomy
had a longer risk-adjusted median hospital stay with 2.61 days
(95% CI, 2.55–2.68) than patients without cholecystectomy
with 2.22 days (95% CI, 2.21–2.23) (p<0.001) (Table 4).
Discussion
We investigated the trend in the practice of concomitant
cholecystectomy during laparoscopic gastric bypass proce-
dures in the USA over an 8-year period. The annual rate of
concomitant cholecystectomy decreased significantly in
patients both with and without gallbladder disease. When
cholecystectomy was performed in addition to laparoscopic
gastric bypass surgery, postoperative adverse outcomes
were more frequent; in particular, we found an increase in
in-hospital mortality and higher rates of infections, pulmo-
nary and gastrointestinal complications, and reinterventions.
The duration of hospital stay was longer in patients
Fig. 1 Percentage of laparoscopic gastric bypass with concomitant cho-
lecystectomy by year; Cochran–Armitage trend test: p for trend<0.001
Fig. 2 a Percentage of laparoscopic gastric bypass without gallbladder
disease with concomitant cholecystectomy by year; Cochran–Armitage
trend test: p for trend<0.001. b Percentage of laparoscopic gastric
bypass with gallbladder disease with concomitant cholecystectomy
by year; Cochran–Armitage trend test: p for trend<0.001
Table 1 (continued)
Variable Without concomitant
cholecystectomy
(n063,885, 90.89%)
With concomitant
cholecystectomy
(n06,402, 9.11%)
p value
2003 4,160 (73.5) 1,501 (26.5)
2004 6,600 (83.8) 1,273 (16.2)
2005 13,897 (93.6) 950 (6.4)
2006 11,640 (93.1) 868 (6.9)
2007 9,920 (94.6) 566 (5.4)
2008 14,992 (96.3) 569 (3.7)
Data are provided as number (n) and percentage, if not otherwise indicated. p values are given for t test and chi-squared test as appropriate
a Cochran–Armitage trend test, p for trend
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undergoing concomitant cholecystectomy compared with
those only undergoing laparoscopic gastric bypass surgery.
Definitive consensus on whether concomitant cholecys-
tectomy should be performed does not yet exist. Still, some
Table 2 Predictors of concomitant cholecystectomy in patients undergoing laparoscopic gastric bypass
Univariate analysis, OR (95% CI) p value Multivariate analysis, OR (95% CI) p value
Year
2001 Ref. Ref.
2002 0.64 (0.52–0.78) <0.001 0.20 (0.13–0.32) <0.001
2003 1.01 (0.84–1.21) 0.919 0.46 (0.31–0.68) <0.001
2004 0.54 (0.45–0.65) <0.001 0.16 (0.11–0.25) <0.001
2005 0.19 (0.16–0.23) <0.001 0.053 (0.035–0.080) <0.001
2006 0.21 (0.17–0.25) <0.001 0.058 (0.038–0.086) <0.001
2007 0.16 (0.13–0.19) <0.001 0.077 (0.050–0.12) <0.001
2008 0.11(0.088–0.13) <0.001 0.042 (0.028–0.063) <0.001
Age 0.997 (0.995–0.9995) 0.019 1.00 (0.0.99–1.01) 0.96
Gender <0.001 0.85
Male Ref. Ref.
Female 1.34(1.24–1.44) 1.02 (0.85–1.22)
Ethnicity
White Ref. Ref.
Black 0.79(0.72–0.87) <0.001 1.03 (0.82–1.30) 0.78
Hispanic 1.18(1.08–1.30) <0.001 0.98 (0.77–1.23) 0.83
Other 0.67(0.57–0.79) <0.001 0.93 (0.64–1.36) 0.72
ZIP code-related income
45,000 or more Ref. Ref.
1–34,999 0.99(0.92–1.06) 0.725 1.06 (0.89–1.27) 0.51
35,000–44,999 0.97(0.91–1.03) 0.323 1.04 (0.89–1.22) 0.62
Insurance
Private including HMO Ref. Ref.
Medicare 0.73(0.66–0.82) <0.001 0.87 (0.66–1.17) 0.36
Medicaid 0.64(0.56–0.73) <0.001 0.73 (0.51–1.03) 0.07
Other 0.73(0.66–0.81) <0.001 1.13 (0.88–1.45) 0.34
Hospital region
South Ref. Ref.
Northeast 0.84(0.78–0.90) <0.001 0.68 (0.56–0.83) <0.001
Midwest 1.10(1.02–1.19) 0.013 0.60 (0.45–0.79) <0.001
West 1.12(1.05–1.19) 0.001 0.69 (0.57–0.83) <0.001
Hospital location/teaching status
Urban nonteaching Ref. Ref.
Rural 0.92(0.78–1.08) 0.31 0.51 (0.31–0.86) 0.011
Urban teaching 0.68(0.64–0.71) <0.001 0.54 (0.46–0.62) <0.001
Deyo score
0 Ref. Ref.
01 0.78 (0.74–0.83) <0.001 0.83 (0.72–0.96) 0.014
>1 0.64 (0.57–0.71) <0.001 0.86 (0.66–1.14) 0.30
Gallbladder disease
No Ref. Ref.
Yes 1019.5 (906.7–1146.2) <0.001 1400.1 (1187.7–1650.4) <0.001
Adjustment for age, gender, ethnicity, Deyo score, gallbladder disease, ZIP code-related income, hospital volume, hospital location/teaching status,
hospital region, insurance status, and year of operation. Total number of patients in the multivariate analysis: n054,124
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authors suggest that every patient should undergo prophy-
lactic cholecystectomy during laparoscopic gastric bypass
surgery [13, 17, 26], while others favor cholecystectomy
only after preoperative confirmation of gallstones [16, 27].
However, there is increasing evidence that cholecystectomy
should only be performed in symptomatic patients since
symptomatic gallbladder disease necessitating cholecystec-
tomy following laparoscopic gastric bypass surgery is as
low as 7% to 15% [11, 19, 22, 28–30]. The limited need
for cholecystectomy in the early follow-up period after
bariatric surgery is in stark contrast to the much higher
incidence of gallstone formation of 30% to 53% within
Table 3 Short-term outcomes after laparoscopic gastric bypass procedure with and without concomitant cholecystectomy (reference category)
Without concomitant
cholecystectomy
(n063,885, 90.89%)
With concomitant
cholecystectomy
(n06,402, 9.11%)
Unadjusted
analysis, OR
(95% CI)
p value Adjusted
analysisa, OR
(95% CI)
p value
Intraoperative complications
Injury to adjacent structures 644 (1.01) 89 (1.39) 1.38 (1.11–1.73) 0.004 0.94 (0.50–1.77) 0.85
Retained foreign body 17 (0.03) 5 (0.08) 2.94 (1.08–7.96) 0.034 N/A N/A
Hemorrhage complicating procedure 890 (1.39) 99 (1.55) 1.11 (0.90–1.37) 0.32 1.25 (0.73–2.15) 0.41
Bile duct complications 3 (0.005) 2 (0.03) 6.65 (1.11–39.82) 0.038 N/A N/A
Overall 1,516 (2.37) 183 (2.86) 1.21 (1.04–1.41) 0.016 1.22 (0.80–1.85) 0.36
Postoperative complications
Mechanical wound complications 318 (0.50) 32 (0.50) 1.00 (0.70–1.45) 0.98 1.62 (0.69–3.84) 0.27
Infections 266 (0.42) 49 (0.77) 1.84 (1.36–2.50) <0.001 3.31 (1.58–6.94) 0.002
Urinary/renal complications 217 (0.34) 27 (0.42) 1.24 (0.83–1.86) 0.29 2.28 (0.90–5.82) 0.08
Pulmonary complications 1,087 (1.70) 150 (2.34) 1.39 (1.17–1.65) <0.001 2.29 (1.53–3.42) <0.001
Gastrointestinal complications 1,122 (1.76) 143 (2.23) 1.28 (1.07–1.52) 0.006 1.88 (1.21–2.91) 0.005
Cardiovascular complications 628 (0.98) 71 (1.11) 1.13 (0.88–1.45) 0.33 1.55 (0.82–2.93) 0.17
Systemic complications 302 (0.47) 33 (0.52) 1.09 (0.76–1.56) 0.64 0.90 (0.35–2.35) 0.83
Overall 3,235 (5.06) 398 (6.22) 1.24 (1.12–1.38) <0.001 1.59 (1.21–2.10) 0.001
Mortality 60 (0.09) 13 (0.2) 2.16 (1.19–3.94) 0.012 N/A N/A
Reintervention 302 (0.47) 47 (0.73) 1.56 (1.14–2.12) 0.005 3.83 (2.00–7.34) <0.001
Conversion rate 1,201 (1.88) 190 (2.97) 1.60 (1.37–1.86) <0.001 1.487 (0.998–2.230) 0.07
Discharge statusb
Nonroutine discharge 2,021 (3.17) 263 (4.12) Ref. Ref.
Routine discharge 61,751 (96.83) 6,121 (95.88) 0.76 (0.67–0.87) <0.001 0.70 (0.49–1.00) 0.05
Due to small outcome events for retained foreign body, bile duct lesions, and mortality, multivariate analysis was not performed for those outcomes
a Adjustment for age, gender, ethnicity, Deyo score, gallbladder disease, ZIP code-related income, hospital volume, hospital location/teaching
status, hospital region, insurance status, and year of operation
b 113 patients in the group without concomitant cholecystectomy and 18 patients in the group with concomitant cholecystectomy have unknown
discharge status
Table 4 Median length of hospital stay with and without concomitant cholecystectomy
Unadjusted Adjusted
Without concomitant
cholecystectomy
With concomitant
cholecystectomy
p value Without concomitant
cholecystectomy
With concomitant
cholecystectomy
p value
Length of hospital stay 2.23 (2.22–2.24) 2.50 (2.47–2.53) <0.001 2.22 (2.21–2.23) 2.61 (2.55–2.68) <0.001
Adjustment for age, gender, ethnicity, Deyo score, gallbladder disease, ZIP code-related income, hospital volume, hospital location/teaching status,
hospital region, insurance status, and year of operation. Values are given as median and 95% CI. Calculations are performed after natural logarithm
transformation, estimates are provided after retransformation
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1 year of the operation [11, 12], but highlights the fact that
not all patients with gallstones require cholecystectomy.
However, the growing evidence that a cholecystectomy after
a laparoscopic gastric bypass procedure can be done in a
minimally invasive fashion with low morbidity is most
likely responsible for the significant decrease in concomi-
tant cholecystectomy [11, 16, 19, 22, 28, 31]. The situation
was different in the era of open gastric bypass procedures
where a postoperative cholecystectomy was difficult to per-
form in a minimally invasive fashion and a second open
procedure was often inevitable. Descriptions of laparoscopic
revisions after open bariatric surgery are not available before
2001 [32, 33].
Our findings suggest that, even if the overall in-
hospital mortality rate is very low, 0.1%, the mortality
rate is significantly higher in patients undergoing concomitant
cholecystectomy. Earlier single-center studies have demon-
strated equal mortality rates for patients with and without
concomitant cholecystectomy [16, 17, 26, 34]. The use of a
large national registry such as the NIS allows for the detection
of even small effects. In our study, the mortality risk is about
twice as high for patients undergoing concomitant cholecys-
tectomy compared with patients who are not.
Despite similar rates of intraoperative complications in
the two groups, we demonstrate that rates of postoperative
complications and reinterventions are higher among patients
undergoing concomitant cholecystectomy. In particular, this
is true for postoperative infections, pulmonary and gastro-
intestinal complications, and reinterventions. The findings
of Hamad and colleagues are consistent with these findings,
suggesting that major early postoperative complications in
patients undergoing concomitant cholecystectomy are more
frequent than in patients not undergoing cholecystectomy
[34]. Nonetheless, others have suggested no difference in
adverse postoperative outcomes [17, 26, 27, 35]. Even
though the absolute risk of those complications in our study
is low, an overall 1.6-fold increase in relative risk still
remains. For bariatric patients, the laparoscopic view is
often impaired through increased visceral fat and hepato-
megaly. Additionally, adding a cholecystectomy to the al-
ready difficult laparoscopic gastric bypass procedure
increases operative time [27, 31] and tissue damage. This
may reduce the function of the right diaphragm and can lead
to increased postoperative pain [36]. The overall lower
preoperative Deyo score among patients undergoing con-
comitant cholecystectomy suggests that their higher rate of
complications postoperatively may be primarily due to the
operation itself rather than the preoperative differences in
comorbidities between the two patient groups.
Postoperative hospital stay was increased by approxi-
mately 0.4 days for patients undergoing concomitant chole-
cystectomy. This finding concurs with those of others who
have demonstrated hospital stays that are 0.6 to 1.7 days
longer for these patients [31, 34]. In contrast, others did not
find any differences in postoperative stay [16, 17, 26, 27].
Even if the increase in length of hospital stay for patients
undergoing concomitant cholecystectomy is small, it should
not be neglected. These findings are consistent with those of
Hamad and colleagues who found a significantly higher
major early postoperative complication rate together with
prolonged hospital stay [34].
This study has several potential limitations. We were
limited by the variables available in the data set. Therefore,
even though multivariable regression analysis is able to
adjust for the measured confounding variables, unmeasured
confounding may still be possible. For example, some
known risk factors for adverse outcomes are unmeasured
in NIS, such as BMI. In addition, the clinical encounter in
the NIS is limited to a single inpatient stay and, as such,
does not capture complications after hospital discharge. The
incidence of cholecystectomy after bariatric surgery is thus
also unknown. The strengths of this analysis are the inclu-
sion of a national cohort and a large sample size and,
therefore, broad generalizability and the power to detect
even small effects.
Conclusions
In essence, the proportion of patients in the USA undergoing
laparoscopic gastric bypass surgery with concomitant cho-
lecystectomy has decreased significantly over time. Given
the much higher rate of adverse short-term postoperative
outcomes in patients undergoing concomitant cholecystec-
tomy and laparoscopic gastric bypass surgery relative to
those undergoing laparoscopic gastric bypass surgery alone,
our findings suggest that concomitant cholecystectomy
should only be indicated for patients with symptomatic
gallbladder disease.
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